搜索
VolitionRX Ltd
VNRX添加自选
1.400USD
+0.020+1.47%
收盘 07/02, 13:00（美东）报价延迟15分钟
555.14K总市值
亏损市盈率 TTM
关键数据
1.350今开
1.460最高
208.73K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
52.64%换手率
1.360昨收
1.320最低
201.75K成交额
亏损市盈率静
-0.02市净率
0.00%股息率 TTM
-281.72%ROA
18.80052周最高
1.76量比
-26.97M净利润
396.53K总股本
-4.2173每股收益TTM
1.06Beta
-5396.85%ROE
1.90652周最低
10.29%振幅
100.00%毛利率
555.14K总市值
-6.00回报/风险
5.33%风险率
TradingKey VolitionRX Ltd股票评分
单位: USD 更新时间: 2026-07-02操作建议
VolitionRX Ltd当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名139/387位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价16.97。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
VolitionRX Ltd评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
VolitionRX Ltd亮点
亮点风险
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
业绩高增长
公司营业收入稳步增长，连续3年增长122.80%
业绩增长期
公司处于发展阶段，最新年度总收入1.73M美元
估值高估
公司最新PE估值-0.33，处于3年历史高位
机构减仓
最新机构持股1.13M股，环比减少15.69%
活跃度降低
近期活跃度降低，过去20天平均换手率-0.83
分析师目标
根据
5
位分析师
买入
评级
16.966
目标均价
+1147.50%
涨幅空间
VolitionRX Ltd新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
VolitionRX Ltd简介
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
公司代码VNRX
公司VolitionRX Ltd
CEOButera (Salvatore Thomas)
网址https://volition.com/
相关品种
热门品种
常见问题
VolitionRX Ltd(VNRX)的当前股价是多少？
VolitionRX Ltd(VNRX)的当前股价是 1.40。
VolitionRX Ltd的股票代码是什么？
VolitionRX Ltd的股票代码是VNRX。
VolitionRX Ltd股票的52周最高点是多少？
VolitionRX Ltd股票的52周最高点是18.80。
VolitionRX Ltd股票的52周最低点是多少？
VolitionRX Ltd股票的52周最低点是1.91。
VolitionRX Ltd的市值是多少？
VolitionRX Ltd的市值是153.47M。
现在VolitionRX Ltd(VNRX)的股票是买入、持有还是卖出？
根据分析师评级，VolitionRX Ltd(VNRX)的总体评级为买入，目标价格为16.97。
VolitionRX Ltd(VNRX)股票的每股收益（EPS TTM）是多少
VolitionRX Ltd(VNRX)股票的每股收益（EPS TTM）是-4.37。